CLEVELAND - A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs’ Endothelial Corneal Dystrophy (FECD), a disease ...

Diabetes, especially type 1 diabetes, may be a particularly important factor in the etiology of Fuchs endothelial corneal dystrophy (FECD) in findings from a case-control study of about 149.000 US ...

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...

SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of ...

Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In a patient with Fuchs’ dystrophy and cataract, PK is the cornea technique of the past and ...

In 1910, Professor Ernst Fuchs, an Austrian ophthalmologist, published an article describing 13 patients with Fuchs’ dystrophy, a condition in the cornea that subsequently bears his name. The patients ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — With an international shortage of donor corneal tissue, a procedure that uses a patient’s own ...